Chemours (CC) Price Target Raised to $66.00 at Jefferies Group
Chemours (NYSE:CC) had its target price raised by equities research analysts at Jefferies Group to $66.00 in a research report issued to clients and investors on Monday, The Fly reports. The brokerage currently has a “buy” rating on the specialty chemicals company’s stock. Jefferies Group’s target price points to a potential upside of 27.31% from the stock’s current price.
Other analysts also recently issued reports about the stock. UBS raised shares of Chemours from a “sell” rating to a “neutral” rating and upped their price objective for the company from $36.00 to $50.00 in a report on Monday, August 7th. Argus reaffirmed a “buy” rating and issued a $55.00 price objective (up from $50.00) on shares of Chemours in a report on Thursday, August 10th. Zacks Investment Research downgraded shares of Chemours from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 12th. Barclays increased their price target on shares of Chemours from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Monday, November 6th. Finally, BidaskClub raised shares of Chemours from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Chemours presently has an average rating of “Buy” and an average target price of $54.56.
Shares of Chemours (CC) opened at $51.84 on Monday. The company has a market cap of $9,598.86, a price-to-earnings ratio of 18.38, a PEG ratio of 0.90 and a beta of 3.38. The company has a quick ratio of 1.63, a current ratio of 2.19 and a debt-to-equity ratio of 5.07. Chemours has a twelve month low of $20.76 and a twelve month high of $58.08.
In other Chemours news, insider E Bryan Snell sold 11,878 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $53.25, for a total transaction of $632,503.50. Following the completion of the transaction, the insider now directly owns 63,063 shares in the company, valued at $3,358,104.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David C. Shelton sold 19,000 shares of the company’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $53.68, for a total transaction of $1,019,920.00. The disclosure for this sale can be found here. Insiders have sold 63,183 shares of company stock worth $3,361,716 over the last three months. 1.14% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of CC. AJO LP acquired a new position in Chemours during the second quarter worth $49,809,000. TIAA CREF Investment Management LLC raised its position in Chemours by 126.5% during the second quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock worth $67,843,000 after acquiring an additional 999,380 shares during the period. Sirios Capital Management L P acquired a new position in Chemours during the second quarter worth $37,430,000. FMR LLC raised its position in Chemours by 6.1% during the second quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock worth $600,289,000 after acquiring an additional 905,038 shares during the period. Finally, Old Mutual Global Investors UK Ltd. acquired a new position in Chemours during the second quarter worth $33,541,000. Institutional investors own 74.42% of the company’s stock.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.